医学
免疫系统
不利影响
CD8型
抗原
接种疫苗
免疫疗法
树突状细胞
食管癌
内科学
免疫学
癌症
T细胞
胃肠病学
作者
Chengshi Wang,Juan Pu,Hanxu Yu,Yanyan Liu,Honghuan Yan,Zhongxiang He,Xin Feng
标识
DOI:10.1097/cji.0000000000000155
摘要
Dendritic cells (DC) are highly efficient antigen-presenting cells. DC may be used to create DC vaccines against cancer, but the optimal strategies remain to be elucidated. This study aimed to examine the benefits and adverse effects of using esophageal cancer cell antigens to stimulate DC to trigger the specific immune response in patients with esophageal cancer undergoing radiotherapy. This was an observational cohort study performed at Lianshui County People’s Hospital between September 2010 and June 2012. Forty patients with esophageal cancer planned to receive radiotherapy were selected, and 28 received the DC vaccine. DC were isolated, loaded with antigens, and intradermally injected after being cultured for 1 week. One week after injection, the patients underwent a delayed-type hypersensitivity test. Serum Th1 cytokines [interleukin (IL)-2, IL-12, and interferon (IFN)-γ] and antigen-specific IFN-γ + CD8 + T cells were tested before and after vaccination. Patients were followed up for 2 years. Adverse events were monitored. Patients in the vaccine group tolerated the DC vaccine. Levels of serum IL-2 (+92.4%), IL-12 (+70.9%), and IFN-γ (+214.3%) as well as the proportion of IFN-γ + CD8 + T cells (3.0–16.4-fold) were significantly increased compared with baseline and the control group (all P <0.05). The 1- (82.1% vs. 50.0%, P =0.04) and 2-year survival (67.8% vs. 33.3%, P =0.04) was improved by vaccination. Only 2 patients showed mild fever. In conclusion, the DC vaccine triggered the specific immune response and induced the secretion of Th1 cytokines. The vaccine may lead to better survival, but this have to be confirmed. Adverse events were rare and mild.
科研通智能强力驱动
Strongly Powered by AbleSci AI